Method of preventing or reducing adverse reactions to protamine using a thromboxane A.sub.2 receptor antagonist
US5066480A · kind A · utility
11Cited by
4References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 1988 |
| Grant date | Nov 19, 1991 |
| Priority date | — |
| Expiry date | Apr 11, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method is provided for preventing reducing or reversing adverse reactions, such as pulmonary hypertension produced when protamine interacts with heparin, by administering a thromboxane A.sub.2 receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.